Using ultrasound to assess liver tumor treatment response
2D and 3D Contrast Enhanced Ultrasound of Chemoembolization
This study is testing if using a special ultrasound during liver cancer treatment can help doctors see how well the treatment is working sooner than traditional imaging methods.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 266 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Thomas Jefferson University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT06261814 on ClinicalTrials.gov |
What this trial studies
This phase II trial evaluates the effectiveness of contrast-enhanced ultrasound (CEUS) in determining how well patients with liver tumors respond to transarterial chemoembolization (TACE). The study aims to compare CEUS with traditional imaging methods like MRI and CT, which assess treatment response weeks after TACE. By using CEUS during the TACE procedure, the trial seeks to provide earlier and potentially more accurate evaluations of treatment effectiveness. Patients will receive an imaging agent and undergo CEUS at multiple points: before, during, and after the TACE procedure.
Who should consider this trial
Good fit: Ideal candidates are adults scheduled for TACE therapy for liver tumors and who are medically stable.
Not a fit: Patients who are medically unstable or have known sensitivities to the components of Lumason may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could allow for quicker and more accurate assessments of liver tumor treatment responses, leading to timely adjustments in therapy.
How similar studies have performed: While CEUS is a promising technique, its application in this specific context is novel and has not been extensively tested in previous studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Scheduled for TACE therapy of a liver tumor * Be at least 18 years of age * Be medically stable * If a female of child-bearing age, must have a negative pregnancy test * Have signed informed consent to participate in the study Exclusion Criteria: * Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable * Patients with known sensitivities to the components of lumason
Where this trial is running
Philadelphia, Pennsylvania
- Sidney Kimmel Cancer Center at Thomas Jefferson University — Philadelphia, Pennsylvania, United States (Recruiting)
Study contacts
- Study coordinator: John Eisenbrey, PhD
- Email: john.eisenbrey@jefferson.edu
- Phone: 215-503-5188
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.